151 related articles for article (PubMed ID: 38678107)
1. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract][Full Text] [Related]
2. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
5. Influence of MTHFR C677T Polymorphism on High-Dose Methotrexate-Related Toxicity in Patients With Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
Chang X; Guo Y; Su L; Zhang Y; Hui W; Zhao H; Hu R; Sun W
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):91-96. PubMed ID: 33069634
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
8. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
[TBL] [Abstract][Full Text] [Related]
9. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
10. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
11. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
12. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Zhao M; Liang L; Ji L; Chen D; Zhang Y; Zhu Y; Ongaro A
Pharmacogenomics; 2016 Jun; 17(9):1005-17. PubMed ID: 27270164
[TBL] [Abstract][Full Text] [Related]
13. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
14. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
16. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
17. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
Tsujimoto S; Yanagimachi M; Tanoshima R; Urayama KY; Tanaka F; Aida N; Goto H; Ito S
Pediatr Blood Cancer; 2016 Nov; 63(11):1983-9. PubMed ID: 27399166
[TBL] [Abstract][Full Text] [Related]
18. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
19. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]